Opportunity Information: Apply for RFA AI 14 013
Apply for RFA AI 14 013
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "HLA and KIR Region Genomics in Immune Mediated Diseases (U19)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.853 Extramural Research Programs in the Neurosciences and Neurological Disorders 93.855 Allergy and Infectious Diseases Research 93.856 Microbiology and Infectious Diseases Research.
- This funding opportunity was created on Jun 9, 2014 and posted on Jun 9, 2014.
- Applicants must submit their applications by Oct 20, 2014. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The funding agency has allocated a total of $3,400,000.00 to eligible and selected applicants.
- Eligible applicants include: Special district governments Others (see text field entitled Additional Information on Eligibility for clarification) For profit organizations other than small businesses State governments Small businesses Independent school districts County governments Native American tribal organizations (other than Federally recognized tribal governments) Public and State controlled institutions of higher education Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Public housing authorities/Indian housing authorities Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Private institutions of higher education Native American tribal governments (Federally recognized) City or township governments.
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Asian American Native American Pacific Islander Serving Institutions (AANAPISISs) Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession Foreign Institutions Non domestic (non U.S.) Entities (Foreign Institutions) are not eligible to apply. Non domestic (non U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The grant opportunity titled "HLA and KIR Region Genomics in Immune Mediated Diseases (U19)" (Funding Opportunity Number RFA-AI-14-013) was a National Institutes of Health (NIH) cooperative agreement intended to build and support a coordinated, multi-project research effort under a consortium structure. The program supports participation in the HLA and KIR Region Genomics in Immune Mediated Diseases Consortium (HLAGC), which was previously named the HLA Region Genomics in Immune Mediated Diseases Consortium. The central scientific focus is on understanding how genetic variation in two highly important immune-related genomic regions, the human leukocyte antigen (HLA) region (also referred to as the Major Histocompatibility Complex, or MHC) and the killer-cell immunoglobulin-like receptor (KIR) region, influences immune mediated diseases and clinically important immune outcomes.
At a practical level, the FOA is aimed at projects that define and clarify associations between HLA/MHC and KIR genetic differences and disease risk, disease mechanisms, and patient outcomes. These regions are well known for being exceptionally variable and immunologically influential. HLA genes are core to antigen presentation and immune recognition, while KIR genes shape natural killer (NK) cell responses, often through interactions with HLA class I molecules. Because of that biology, variation in either region, and especially combinations of variation across both regions, can meaningfully affect susceptibility to autoimmune and inflammatory conditions, responses to infections, and outcomes after clinical interventions where immune compatibility matters. The announcement explicitly notes transplantation-related outcomes as a key area of interest, including outcomes following cell, tissue, and organ transplantation, where HLA matching, immune activation, rejection risk, graft-versus-host disease, and infection susceptibility can be influenced by both HLA and KIR genetics.
The funding mechanism is a U19 cooperative agreement, which typically indicates NIH expects substantial programmatic involvement beyond a standard investigator-initiated grant. In other words, awardees are not simply funded to do independent projects; they are expected to operate as part of a cooperative research group with shared goals, coordinated plans, and consortium-level collaboration. The structure usually implies shared standards for data generation and analysis, coordination across projects, and active engagement with consortium governance, working groups, and NIH scientific staff oversight. The emphasis on a consortium also suggests the FOA is oriented toward producing resources, datasets, methods, and harmonized analyses that have broader value to the research community, rather than isolated single-lab studies.
The opportunity was categorized as discretionary funding and fell under the health activity category, with CFDA numbers listed as 93.853 (Extramural Research Programs in the Neurosciences and Neurological Disorders), 93.855 (Allergy and Infectious Diseases Research), and 93.856 (Microbiology and Infectious Diseases Research). That mix reflects how HLA and KIR genomics can cut across autoimmune disease, infectious disease, transplantation immunology, and immune-driven neurologic conditions. The agency named is the NIH, and the announcement was posted and created on June 9, 2014. The original and current closing date were both October 20, 2014, and the announcement was archived on November 20, 2014, indicating it is no longer open for applications.
The estimated total funding amount listed for the FOA was $3,400,000, and the FOA stated there was no cost sharing or matching requirement. Eligibility was broad and included many types of U.S.-based organizations and governmental units. Eligible applicants included state governments, county governments, city or township governments, special district governments, independent school districts, and public housing authorities/Indian housing authorities. A wide range of academic and nonprofit entities were eligible, including public and state-controlled institutions of higher education, private institutions of higher education, nonprofits with 501(c)(3) status (other than institutions of higher education), and nonprofits without 501(c)(3) status (other than institutions of higher education). Small businesses and for-profit organizations other than small businesses were also eligible, as were Native American tribal governments (federally recognized) and Native American tribal organizations (other than federally recognized tribal governments).
The eligibility section also called out additional eligible applicant categories, including historically underrepresented and mission-focused institutions such as Historically Black Colleges and Universities (HBCUs), Hispanic-serving institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, and Asian American Native American Pacific Islander Serving Institutions (AANAPISIs). Faith-based or community-based organizations and regional organizations were also listed among other eligible applicants. Importantly, the FOA specified that foreign institutions and non-domestic (non-U.S.) entities were not eligible to apply, and non-domestic components of U.S. organizations were not eligible either. However, it allowed "foreign components" as defined in the NIH Grants Policy Statement, meaning a U.S. applicant could potentially include certain types of international collaboration elements if they met NIH policy definitions and requirements.
For applicants or interested parties seeking the full text, the FOA provided an additional information link hosted on the NIH grants site (http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-14-013.html). The contact information provided in the source data is for technical difficulty accessing the announcement, directing users to the NIH Office of Extramural Research (OER) webmaster at FBOWebmaster@OD.NIH.GOV.
FAQs: HLA and KIR Region Genomics in Immune Mediated Diseases (U19) (RFA-AI-14-013)
What is the title and funding opportunity number for this grant?
The opportunity is titled "HLA and KIR Region Genomics in Immune Mediated Diseases (U19)" and the Funding Opportunity Number (FOA) is RFA-AI-14-013.
Which agency offered this funding opportunity?
The agency is the National Institutes of Health (NIH).
What type of funding mechanism is this?
This FOA uses a U19 cooperative agreement mechanism, which is designed for coordinated, multi-project research efforts organized under a consortium structure.
What does a U19 cooperative agreement imply for awardees?
A U19 cooperative agreement generally implies substantial NIH programmatic involvement and active consortium-style coordination. Awardees are expected to operate as part of a cooperative research group with shared goals, coordinated plans, and consortium-level collaboration rather than running fully independent, stand-alone projects.
What consortium is associated with this FOA?
The FOA supports participation in the HLA and KIR Region Genomics in Immune Mediated Diseases Consortium (HLAGC), which was previously named the HLA Region Genomics in Immune Mediated Diseases Consortium.
What is the central scientific focus of the program?
The central focus is understanding how genetic variation in two key immune-related genomic regions, the HLA region (also called the Major Histocompatibility Complex, or MHC) and the KIR region, influences immune mediated diseases and clinically important immune outcomes.
Which genomic regions are emphasized?
The FOA emphasizes the human leukocyte antigen (HLA)/Major Histocompatibility Complex (MHC) region and the killer-cell immunoglobulin-like receptor (KIR) region.
What kinds of research questions is the FOA aimed at?
At a practical level, the FOA is aimed at projects that define and clarify associations between HLA/MHC and KIR genetic differences and disease risk, disease mechanisms, and patient outcomes.
Why are the HLA and KIR regions considered important in immunology?
The FOA highlights that these regions are exceptionally variable and immunologically influential. HLA genes are central to antigen presentation and immune recognition, while KIR genes shape natural killer (NK) cell responses, often through interactions with HLA class I molecules.
Does the FOA emphasize interactions between HLA and KIR variation?
Yes. The description notes that variation in either region, and especially combinations of variation across both regions, can meaningfully affect susceptibility to immune mediated diseases and clinically important immune outcomes.
What disease areas or outcomes are mentioned as relevant?
The FOA description ties the science to autoimmune and inflammatory conditions, responses to infections, and outcomes after clinical interventions where immune compatibility matters.
Are transplantation-related outcomes included?
Yes. The announcement explicitly notes transplantation-related outcomes as a key area of interest, including outcomes following cell, tissue, and organ transplantation.
What transplantation factors does the FOA mention?
It mentions that HLA matching, immune activation, rejection risk, graft-versus-host disease, and infection susceptibility can be influenced by both HLA and KIR genetics.
Is this opportunity intended for single-lab projects or coordinated efforts?
It is intended to build and support a coordinated, multi-project research effort under a consortium structure, with coordinated plans and shared goals.
Does the FOA suggest producing shared resources or harmonized outputs?
Yes. The description emphasizes consortium-level collaboration and suggests shared standards for data generation and analysis, coordination across projects, and harmonized analyses with broader value beyond isolated studies.
What is the estimated total funding amount for this FOA?
The estimated total funding amount listed is $3,400,000.
Is cost sharing or matching required?
No. The FOA states there was no cost sharing or matching requirement.
How is this opportunity categorized in terms of funding type and activity?
It was categorized as discretionary funding and fell under the health activity category.
Which CFDA numbers are associated with this FOA?
The CFDA numbers listed are 93.853 (Extramural Research Programs in the Neurosciences and Neurological Disorders), 93.855 (Allergy and Infectious Diseases Research), and 93.856 (Microbiology and Infectious Diseases Research).
When was the announcement posted and created?
The announcement was posted and created on June 9, 2014.
What were the application closing dates?
The original closing date and the current closing date were both October 20, 2014.
Is this FOA still open for applications?
No. The announcement was archived on November 20, 2014, indicating it is no longer open for applications.
What types of U.S. government entities were eligible to apply?
Eligible applicants included state governments, county governments, city or township governments, special district governments, independent school districts, and public housing authorities/Indian housing authorities.
Were colleges and universities eligible?
Yes. Public and state-controlled institutions of higher education and private institutions of higher education were eligible.
Were nonprofit organizations eligible?
Yes. Nonprofits with 501(c)(3) status (other than institutions of higher education) and nonprofits without 501(c)(3) status (other than institutions of higher education) were eligible.
Were businesses eligible to apply?
Yes. Small businesses and for-profit organizations other than small businesses were eligible.
Were Native American tribal governments or tribal organizations eligible?
Yes. Native American tribal governments (federally recognized) and Native American tribal organizations (other than federally recognized tribal governments) were eligible.
Were specific mission-focused or historically underrepresented institutions listed as eligible?
Yes. The FOA listed several categories, including Historically Black Colleges and Universities (HBCUs), Hispanic-serving institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, and Asian American Native American Pacific Islander Serving Institutions (AANAPISIs).
Were faith-based or community-based organizations eligible?
Yes. Faith-based or community-based organizations were listed among other eligible applicants.
Were regional organizations eligible?
Yes. Regional organizations were listed among other eligible applicants.
Are foreign (non-U.S.) institutions eligible to apply directly?
No. The FOA specified that foreign institutions and non-domestic (non-U.S.) entities were not eligible to apply.
Are non-domestic components of U.S. organizations eligible?
No. The FOA specified that non-domestic components of U.S. organizations were not eligible.
Does the FOA allow any type of international involvement?
Yes, in a limited way. It allowed "foreign components" as defined in the NIH Grants Policy Statement, meaning a U.S. applicant could potentially include certain types of international collaboration elements if they meet NIH policy definitions and requirements.
Where can applicants find the full FOA text?
The FOA provided an NIH grants link for additional information: http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-14-013.html
Who is the listed contact for technical difficulties accessing the announcement?
For technical difficulty accessing the announcement, the FOA directs users to contact the NIH Office of Extramural Research (OER) webmaster at FBOWebmaster@OD.NIH.GOV.
Browse more opportunities from the same category: Health
Next opportunity: BLM CA Headwaters Forest Reserve Community Stewardship Ed Program
Previous opportunity: HLA and KIR Region Genomics in Immune Mediated Diseases (U01)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA AI 14 013
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (RFA AI 14 013) also looked into and applied for these:
| Funding Opportunity |
|---|
| Cooperative Agreement to Support Navigators in Federally facilitated and State Partnership Marketplaces Apply for CA NAV 14 002 Funding Number: CA NAV 14 002 Agency: CMS Consumer Information Insurance Oversight Category: Health Funding Amount: Case Dependent |
| Advancing National Public Health Institutes Globally Apply for CDC RFA GH14 1419 Funding Number: CDC RFA GH14 1419 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| NIOSH Support for Conferences and Scientific Meetings (R13) Apply for PAR 14 246 Funding Number: PAR 14 246 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $20,000 |
| Research Supplements for Aging Research on Health Disparities (Admin Supp) Apply for PA 14 256 Funding Number: PA 14 256 Agency: National Institutes of Health Category: Health Funding Amount: $62,500 |
| Training Seminars on Safe Medicine Apply for NDRFP14 05 Funding Number: NDRFP14 05 Agency: U.S. Mission to India Category: Health Funding Amount: $14,000 |
| Mentored Career Development Award to Build Research Capacity in Global Mental Health (K01) Apply for RFA MH 15 700 Funding Number: RFA MH 15 700 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NIMH Biobehavioral Research Awards for Innovative New Scientists (NIMH BRAINS) (R01) Apply for RFA MH 15 600 Funding Number: RFA MH 15 600 Agency: National Institutes of Health Category: Health Funding Amount: $400,000 |
| Severe Combined Immunodeficiency (SCID) Newborn Screening Implementation Program Apply for HRSA 14 139 Funding Number: HRSA 14 139 Agency: Health Resources and Services Administration Category: Health Funding Amount: $2,000,000 |
| Leadership in Public Health Social Work Education Apply for HRSA 14 145 Funding Number: HRSA 14 145 Agency: Health Resources and Services Administration Category: Health Funding Amount: $300,000 |
| Improving Effectiveness of the Tuberculosis Prevention and Control Programs in Resource Limited Countries Apply for CDC RFA PS14 1411 Funding Number: CDC RFA PS14 1411 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $1,000,000 |
| Health Careers Opportunity Program Skills Training and Health Workforce Development of Paraprofessionals Apply for HRSA 14 144 Funding Number: HRSA 14 144 Agency: Health Resources and Services Administration Category: Health Funding Amount: $200,000 |
| Tribal Public Health Capacity Building and Quality Improvement Cooperative Agreement Apply for CDC RFA OT13 130302CONT14 Funding Number: CDC RFA OT13 130302CONT14 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| Parkinsons Disease Biomarker Program (PDBP) Discovery Projects (U01) Apply for PAR 14 259 Funding Number: PAR 14 259 Agency: National Institutes of Health Category: Health Funding Amount: $490,000 |
| Centers for Medical Countermeasures against Radiation Consortium (U19) Apply for RFA AI 14 055 Funding Number: RFA AI 14 055 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| PPHF 2014 Racial and Ethnic Approaches to Community Health (REACH) financed in part by Prevention and Public Health Funding Apply for CDC RFA DP14 1419PPHF14 Funding Number: CDC RFA DP14 1419PPHF14 Agency: NCCDPHP Category: Health Funding Amount: $500,000 |
| PPHF 2014 Immunization Capacity Building Assistance for Infrastructure Enhancements to Meet Interoperability Requirements financed in part by 2014 Prevention and Public Health Funds Apply for CDC RFA IP14 1404PPHF14 Funding Number: CDC RFA IP14 1404PPHF14 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $2,000,000 |
| Methods Development in Natural Products Chemistry (R43/R44) Apply for RFA AT 15 003 Funding Number: RFA AT 15 003 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Methods Development in Natural Products Chemistry (STTR) (R41) Apply for RFA AT 15 002 Funding Number: RFA AT 15 002 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| American Indians into Psychology Apply for HHS 2014 IHS INPSY 0001 Funding Number: HHS 2014 IHS INPSY 0001 Agency: Indian Health Service Category: Health Funding Amount: $238,359 |
| PPHF 2014 Immunization Enhanced Standards Support for the Immunization Information Systems (IIS) Community Financed solely by 2014 Prevention and Public Health Funds Apply for CDC RFA IP14 1409PPHF14 Funding Number: CDC RFA IP14 1409PPHF14 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $1,000,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA AI 14 013", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.